Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
City Therapeutics, Inc. stock logo
CTY
City Therapeutics
$19.32
+5.3%
$0.00
$15.81
▼
$23.88
$999.23MN/A285,741 shs250,121 shs
Tempus AI, Inc. stock logo
TEM
Tempus AI
$53.98
-9.5%
$72.89
$40.77
▼
$89.09
$9.85B3.616.23 million shs7.41 million shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
City Therapeutics, Inc. stock logo
CTY
City Therapeutics
+10.28%-3.32%-11.91%+1,834,999,900.00%+1,834,999,900.00%
Tempus AI, Inc. stock logo
TEM
Tempus AI
-6.30%-21.45%-10.70%-17.99%-13.72%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
City Therapeutics, Inc. stock logo
CTY
City Therapeutics
$19.32
+5.3%
$0.00
$15.81
▼
$23.88
$999.23MN/A285,741 shs250,121 shs
Tempus AI, Inc. stock logo
TEM
Tempus AI
$53.98
-9.5%
$72.89
$40.77
▼
$89.09
$9.85B3.616.23 million shs7.41 million shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
City Therapeutics, Inc. stock logo
CTY
City Therapeutics
+10.28%-3.32%-11.91%+1,834,999,900.00%+1,834,999,900.00%
Tempus AI, Inc. stock logo
TEM
Tempus AI
-6.30%-21.45%-10.70%-17.99%-13.72%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
City Therapeutics, Inc. stock logo
CTY
City Therapeutics
3.00
Buy$37.3384.82% Upside
Tempus AI, Inc. stock logo
TEM
Tempus AI
2.45
Hold$79.3741.68% Upside

Current Analyst Ratings Breakdown

Latest BGSC, RCP, CTY, and TEM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/19/2026
Tempus AI, Inc. stock logo
TEM
Tempus AI
Reiterated RatingBuy$85.00
11/16/2026
City Therapeutics, Inc. stock logo
CTY
City Therapeutics
Initiated CoverageStrong-Buy
11/11/2026
City Therapeutics, Inc. stock logo
CTY
City Therapeutics
Initiated CoverageHold
11/10/2026
City Therapeutics, Inc. stock logo
CTY
City Therapeutics
Initiated CoverageBuy$34.00
11/10/2026
City Therapeutics, Inc. stock logo
CTY
City Therapeutics
Initiated CoverageBuy$32.00
11/10/2026
City Therapeutics, Inc. stock logo
CTY
City Therapeutics
Initiated CoverageOutperform$46.00
11/3/2026
Tempus AI, Inc. stock logo
TEM
Tempus AI
Boost Price TargetBuy$80.00 ➝ $100.00
11/3/2026
Tempus AI, Inc. stock logo
TEM
Tempus AI
UpgradeUnderperform ➝ Hold$35.00 ➝ $70.00
11/3/2026
Tempus AI, Inc. stock logo
TEM
Tempus AI
Boost Price TargetOverweight$80.00 ➝ $92.00
11/3/2026
Tempus AI, Inc. stock logo
TEM
Tempus AI
Boost Price TargetOutperform$85.00 ➝ $92.00
11/3/2026
Tempus AI, Inc. stock logo
TEM
Tempus AI
Boost Price TargetBuy$68.00 ➝ $85.00
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
City Therapeutics, Inc. stock logo
CTY
City Therapeutics
N/AN/AN/AN/AN/AN/A
Tempus AI, Inc. stock logo
TEM
Tempus AI
$1.27B8.03N/AN/A$2.74 per share20.44
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
City Therapeutics, Inc. stock logo
CTY
City Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Tempus AI, Inc. stock logo
TEM
Tempus AI
-$245.03M-$1.06N/AN/AN/A-12.54%-47.00%-9.44%N/A

Latest BGSC, RCP, CTY, and TEM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/2/2026Q3 2026
Tempus AI, Inc. stock logo
TEM
Tempus AI
-$0.0937$0.07+$0.1637-$0.08$409.39 million$411.54 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
City Therapeutics, Inc. stock logo
CTY
City Therapeutics
N/AN/AN/AN/AN/A
Tempus AI, Inc. stock logo
TEM
Tempus AI
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
City Therapeutics, Inc. stock logo
CTY
City Therapeutics
N/AN/AN/A
Tempus AI, Inc. stock logo
TEM
Tempus AI
2.70
2.61
2.48

Institutional Ownership

CompanyInstitutional Ownership
City Therapeutics, Inc. stock logo
CTY
City Therapeutics
N/A
Tempus AI, Inc. stock logo
TEM
Tempus AI
24.22%

Insider Ownership

CompanyInsider Ownership
City Therapeutics, Inc. stock logo
CTY
City Therapeutics
N/A
Tempus AI, Inc. stock logo
TEM
Tempus AI
24.26%
CompanyEmployeesShares OutstandingFree FloatOptionable
City Therapeutics, Inc. stock logo
CTY
City Therapeutics
7551.72 millionN/AN/A
Tempus AI, Inc. stock logo
TEM
Tempus AI
3,800182.40 million138.15 millionOptionable

Recent News About These Companies

Tempus AI (NASDAQ:TEM) EVP Sells $422,486.08 in Stock
Top Artificial Intelligence Stocks To Follow Today - November 19th
What's Going To Happen With Tempus AI Stock Soon?
Tempus AI (NASDAQ:TEM) Stock Keeps "Buy" Rating at HC Wainwright
Tempus AI: 3 Key Takeaways for Long-Term Investors
Tempus Ai, Inc. Extends Strategic Collaboration with Astrazeneca AB
Best Artificial Intelligence Stocks To Follow Now - November 18th
Tempus AI and AstraZeneca Extend Strategic Services Agreement
Tempus AI, Inc. (TEM)
Artificial Intelligence Stocks To Follow Now - November 17th
Tempus AI (NASDAQ:TEM) Shares Gap Up - Time to Buy?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
City Therapeutics stock logo

City Therapeutics NASDAQ:CTY

$19.32 +0.97 (+5.29%)
As of 04:00 PM Eastern

We are a clinical-stage biotechnology company developing the next generation of RNA interference (“RNAi”) therapeutics designed to silence the expression of disease-relevant proteins, with the aim of delivering meaningful and durable benefits for patients in need. We believe our deep RNAi expertise and City Platform capabilities uniquely position us to achieve our goal of developing potentially best-in-class therapeutics. Our vision is to lead the next generation of RNAi therapeutics, and our mission is to improve patients’ lives through breakthrough RNAi science as we build a biopharmaceutical company with enduring impact. Our current pipeline is focused on indications with significant unmet medical need, including thromboembolic diseases, Stargardt disease type 1 (“Stargardt disease”), and anemia of chronic disease, where we believe disease biology supports RNAi-mediated knockdown as a differentiated approach compared to other modalities. Led by pioneers and experts in the field of RNAi, we have made rapid progress since founding our company in July 2023, discovering and advancing three programs into or toward the clinic in under three years, and our goal is for our City Platform to deliver one to two new investigational new drug application (“IND”) or IND-equivalent applications per year. Several members of our leadership team, including John Maraganore, Ph.D., our co-founder and Executive Chair and former founding Chief Executive Officer of Alnylam Pharmaceuticals, Inc. (“Alnylam”), and Tracy Zimmermann, Ph.D., our Chief Scientific Officer, played a foundational role in establishing RNAi therapeutics as a recognized treatment modality, as evidenced by multiple FDA-approved RNAi therapeutics that each of them worked in development on, and our President and Chief Executive Officer, Andrew (Andy) Orth, M.B.A., led the launch of multiple RNAi therapeutics, including the first U.S. Food and Drug Administration (“FDA”)-approved RNAi therapeutic. Collectively, the team at City has contributed to the discovery, development, or commercialization of seven of the eight currently FDA-approved RNAi therapeutics, and 75% of our research leaders have prior RNAi therapeutics discovery or development experience. RNAi is a naturally occurring biological process that regulates or silences gene expression by “interfering” with messenger RNA (“mRNA”) before it can be translated into protein. RNAi has inherent advantages as a therapeutic mechanism because it is a highly specific, potent, and durable approach to selectively silence the expression of disease-relevant proteins, including intracellular targets that are inaccessible to traditional small molecules and antibodies. In addition, RNAi therapeutics benefit from a simpler molecular architecture relative to biologics, consisting of short, chemically synthesized oligonucleotides rather than large, complex proteins, which enables more consistent and scalable manufacturing. RNAi has been established mechanistically and commercially, with the first of the eight FDA-approved RNAi therapeutics coming to market in 2018 and multiple products achieving substantial and growing commercial sales. With approximately 100 programs currently in clinical development, we believe RNAi therapeutics are poised to follow a growth trajectory analogous to that of monoclonal antibody therapeutics, a modality that was first approved by the FDA in the mid-1990s and has since expanded to more than 150 approved medicines. While RNAi is an established therapeutic modality, we are early in our development efforts, and our City Platform and approach to the engineering and development of certain of our product candidates is unproven and incorporates novel technologies that may not result in marketable products. Our lead product candidate, CITY-FXI, is in an early stage of clinical development, and our other product candidates and development programs are in preclinical development or drug discovery. We have only recently initiated our first clinical trial, have not yet completed any clinical trials, and have limited experience conducting and managing clinical trials. None of our product candidates has been approved for commercial sale, we have not generated revenue from product sales, and we have not yet demonstrated an ability to successfully complete clinical development or obtain marketing approval for and commercialize any of our product candidates. Our product candidates may fail in development or never receive regulatory approval, and we will require substantial additional capital to complete development of and, if approved, commercialize our product candidates. We were incorporated under the laws of the State of Delaware in July 2023. Our principal executive offices are located in Cambridge, Massachusetts.

Tempus AI stock logo

Tempus AI NASDAQ:TEM

$53.98 -5.63 (-9.45%)
Closing price 03:58 PM Eastern
Extended Trading
$54.88 +0.90 (+1.67%)
As of 05:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Tempus AI Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. Tempus AI Inc. is based in CHICAGO.